Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

Methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum

DNA methylation testing

Lei Li, M.D.

Ming Wu, M.D.

Lei Li, MD

Liquid biopsy is challenging for the diagnosis of epithelial ovarian cancer (EOC). In this study, we performed the methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum to discover the diagnostic and supervision roles of DNA methylation in EOC patients. The study compromises two stages.

In the training set, DNA methylation testing is performed in the ovarian tissues from EOC and paired benign ovarian tumor patients. The cut-off values of methylation are produced in this stage. On the meantime, serum DNA methylation testing is also performed to reveal its accordance and accuracy compared with the results of ovarian tissues.

In the validation set, serum DNA methylation testing is performed in unselected ovarian tumor patients with definite cut-off values to validate its accuracy based on known histology of ovarian tumors.

In training and validation sets, serum DNA methylation is also performed after major surgeries for EOC as to illustrate the changes of methylation testing, therefore, reflection the supervision role of DNA methylation.

All eligible patients accept DNA methylation testing in serum and in ovarian tissues.

Cell-free DNA Methylation for Epithelial Ovarian Cancer

Cell-free DNA Methylation for the Diagnosis and Monitoring of Epithelial Ovarian Cancer: The Training and Validation Sets in China

The cut-off values are achieve by paired epithelial ovarian cancer and benign ovarian tumor patients.

The accuracy is supported by sensitivity, specificity, negative predictive value and positive predictive value.

Lei Li

Professor

Endometrial Neoplasms

Uterine Neoplasms

Uterine Diseases

All eligible participants consenting to participate the study.

Methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177

Liquid biopsy is challenging for the diagnosis of endometrial cancer. In this study, investigators perform the methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177, in the peripheral serum to discover the diagnostic and supervision roles of DNA methylation in endometrial cancer. The study compromises two stages.

In the training set, DNA methylation testing is performed in the endometrial tissues from patients with endometrial cancer and paired benign uterine lesions. The cut-off values of methylation are produced in this stage. On the meantime, DNA methylation testing is also performed in serum and in cervical cytology to reveal its accordance and accuracy compared with the results of endometrial tissues.

In the validation set, serum DNA methylation testing is performed in unselected patients with definite endometrial histology to validate its accuracy.

In training and validation sets, serum DNA methylation is also performed after major surgeries for endometrial cancer as to illustrate the changes of methylation testing, therefore, reflection the supervision role of DNA methylation.

All eligible patients accept DNA methylation testing in serum, cervical cytology and endometrial tissues.

Cell-free DNA Methylation for Endometrial Cancer

Cell-free DNA Methylation for the Diagnosis and Monitoring of Endometrial Cancer: The Training and Validation Sets in China

The cut-off values are achieved by paired endometrial cancer and benign uterine tumor patients

The accuracy is supported by sensitivity, specificity, negative predictive value and positive predictive value

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cell-free DNA Methylation for Epithelial Ovarian Cancer	NCT04651946	Epithelial Ovar... DNA Methylation Benign Ovarian ... Training Set Validation Set Cell-free DNA Liquid Biopsy	DNA methylation...	18 Years -	Peking Union Medical College Hospital
Cell-free DNA Methylation for Epithelial Ovarian Cancer	NCT04651946	Epithelial Ovar... DNA Methylation Benign Ovarian ... Training Set Validation Set Cell-free DNA Liquid Biopsy	DNA methylation...	18 Years -	Peking Union Medical College Hospital
Cell-free DNA Methylation for Endometrial Cancer	NCT04651738	Endometrial Can... Liquid Biopsy DNA Methylation Cervical Cytolo... Diagnostic Accu... Training Set Validation Set	DNA methylation...	18 Years -	Peking Union Medical College Hospital
Cell-free DNA Methylation for Endometrial Cancer	NCT04651738	Endometrial Can... Liquid Biopsy DNA Methylation Cervical Cytolo... Diagnostic Accu... Training Set Validation Set	DNA methylation...	18 Years -	Peking Union Medical College Hospital

Spots Global Cancer Trial Database for validation set